Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$55.47 USD

55.47
3,077,855

-0.07 (-0.13%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: SNY, GSK, AZN's Coronavirus Vaccines/Treatments Progress

by Kinjel Shah

AstraZeneca (AZN) begins phase III study on COVID-19 vaccine candidate in the United States. Sanofi (SNY)/Glaxo's (GSK) vaccine enters clinical stage.

Ritujay Ghosh headshot

Vaccine Hopes Rise Again: 4 Stocks to Watch

by Ritujay Ghosh

The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and Sanofi (SNY).

Sanofi, Glaxo Start Clinical Study on Coronavirus Vaccine

by Zacks Equity Research

Sanofi (SNY) and Glaxo have a collaboration to develop an adjuvant vaccine against coronavirus.

Is Sanofi (SNY) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sanofi's Kevzara Fails as a Potential COVID-19 Treatment

by Zacks Equity Research

Sanofi's (SNY) phase III study evaluating Kevzara in severely or critically ill patients hospitalized with COVID-19 fails to meet primary endpoint and key secondary endpoint.

Sweta Killa headshot

5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks

by Sweta Killa

While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.

Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study

by Zacks Equity Research

Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.

FDA Nods to Novartis' Kesimpta for Relapsing Forms of MS

by Zacks Equity Research

Novartis (NVS) gains an FDA nod for Kesimpta (ofatumumab) as a subcutaneous injection for relapsing multiple sclerosis. The drug is expected to be available early next month.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals

by Kinjel Shah

J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma

Glaxo Initiates Dosing in Phase III Meningitis Vaccine Study

by Zacks Equity Research

Glaxo (GSK) starts dosing with a phase III study on it 5-in-1 meningitis vaccine candidate.

J&J to Buy Momenta for $6.5B to Boost Autoimmune Presence

by Zacks Equity Research

J&J (JNJ) offers to buy Momenta, which focuses on the development of novel drugs to treat rare, immune-mediated disorders.

Momenta Surges on Acquisition Deal With Johnson & Johnson

by Zacks Equity Research

Momenta (MNTA) soars on the announcement of being acquired by Johnson & Johnson for $6.5 billion.

Regeneron, Roche to Distribute Antibody Cocktail for Coronavirus

by Zacks Equity Research

Regeneron (REGN) teams up with Roche to develop and distribute REGN-COV2, its experimental dual antibody cocktail for the prevention and treatment of COVID-19.

Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa

by Zacks Equity Research

Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.

FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension

by Zacks Equity Research

Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.

Stock Market News for Aug 18, 2020

by Zacks Equity Research

U.S. stock markets were mixed on Monday in absence of any major news and low trading volume.

Sheraz Mian headshot

Top Analyst Reports for JPMorgan, NVIDIA & Toyota Motor

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), NVIDIA (NVDA) and Toyota Motor (TM).

Pre-Markets Stay Green, Big Week for Retail Sector Earnings

by Zacks Equity Research

Stock futures point to a higher opening on Monday after three consecutive weeks of a rally.

Retail Earnings Week Ahead

by Zacks Equity Research

Retail Earnings Week Ahead

Sanofi to Buy Immunology Firm Principia Biopharma for $3.7B

by Zacks Equity Research

Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.

Regeneron's BLA for Cholesterol Drug Accepted by the FDA

by Zacks Equity Research

The FDA accepts Regeneron's (REGN) application for evinacumab in HoFH, with priority review.

Ritujay Ghosh headshot

US Continues to Secure Coronavirus Vaccines: 4 Stocks to Watch

by Ritujay Ghosh

The deal with Moderna yet again renewed hopes among millions about a possible vaccine by the end of this year.

Moderna Up on $1.5B Federal Funding for Coronavirus Vaccine

by Zacks Equity Research

Moderna (MRNA) inks a deal with the U.S. government for supplying 100 million doses of mRNA-1273, its vaccine against COVID-19. Shares rise in pre-market trading.

Novavax's (NVAX) Earnings Beat in Q2, Sales Lag Estimates

by Zacks Equity Research

Novavax's (NVAX) loss narrows for the second quarter of 2020 but revenues miss the mark.

Ritujay Ghosh headshot

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

by Ritujay Ghosh

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.